Case of right ventricular and aortic thrombi in a patient with severe COVID-19

BMJ Case Rep. 2021 Apr 19;14(4):e240745. doi: 10.1136/bcr-2020-240745.

Abstract

Emerging evidence suggests that novel COVID-19 is associated with increased prothrombotic state and risk of thromboembolic complications, particularly in severe disease. COVID-19 is known to predispose to both venous and arterial thrombotic disease. We describe a case of a 61-year-old woman with history of type II diabetes, hypertension and hyperlipidaemia who presented with dry cough and acute abdominal pain. She was found to have a significantly elevated D-dimer, prompting imaging that showed thrombi in her right ventricle and aorta. She had rapid clinical deterioration and eventually required tissue plasminogen activator with subsequent durable clinical improvement. This case highlights a rare co-occurrence of venous and arterial thrombi in a patient with severe COVID-19. Further studies are needed to clarify the molecular mechanism of COVID-19 coagulopathy, the utility of D-dimer to predict and stratify risk of thrombosis in COVID-19, and the use of fibrinolytic therapy in patients with COVID-19.

Keywords: COVID-19; haematology (incl blood transfusion); venous thromboembolism.

Publication types

  • Case Reports

MeSH terms

  • Aorta / pathology
  • COVID-19* / complications
  • Diabetes Mellitus, Type 2* / complications
  • Female
  • Fibrin Fibrinogen Degradation Products / analysis
  • Heart Ventricles / diagnostic imaging
  • Heart Ventricles / pathology
  • Humans
  • Middle Aged
  • Thrombosis* / complications
  • Thrombosis* / diagnostic imaging
  • Thrombosis* / drug therapy
  • Tissue Plasminogen Activator / therapeutic use

Substances

  • Fibrin Fibrinogen Degradation Products
  • fibrin fragment D
  • Tissue Plasminogen Activator